ARS Pharmaceuticals, Inc. Piotroski F-Score
SPRY / Health Care|Based on FY2025 SEC 10-K data
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -1.44 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
ARS Pharmaceuticals, Inc.'s Piotroski F-Score of 2/9 indicates significant financial concerns, passing 2 of 9 criteria (FY2025). The score evaluates profitability, leverage, and operating efficiency from ARS Pharmaceuticals, Inc.'s SEC 10-K filing.
Based on SEC 10-K filings.
Significant financial concerns
The Piotroski F-Score evaluates financial strength using 9 binary criteria across profitability, leverage, and operating efficiency. Learn how it works
Profit margin ranks in the above average of Health Care companies
What This Score Means
ARS Pharmaceuticals, Inc. scores 2/9 on the Piotroski F-Score based on FY2025 SEC 10-K data. Only 1 of 4 profitability criteria are met, pointing to potential earnings concerns. Leverage and liquidity show no improvement (0/3 criteria met). One of two operating efficiency metrics improved, while the other declined.
The Piotroski F-Score is a financial strength indicator based on 9 binary criteria from SEC 10-K filings. Scores of 8-9 suggest strong fundamentals, while 0-2 may indicate financial weakness. This is not investment advice.
9-Criterion Breakdown
1. Positive Net Income
Net Income > 0
2. Positive Operating Cash Flow
Operating Cash Flow > 0
3. ROA Increase
Return on Assets improved year-over-year
4. Quality of Earnings
Operating Cash Flow > Net Income
5. Leverage Decrease
Debt-to-assets ratio decreased or unchanged
6. Current Ratio Increase
Current ratio improved year-over-year
7. No Share Dilution
Shares outstanding did not increase
8. Gross Margin Increase
Gross margin improved year-over-year
9. Asset Turnover Increase
Revenue / Total Assets improved
As of FY2025 · SEC 10-K · Updated Jun 30, 2026